Motors, I agree with your numbers and the overhanging question on the current leadership of the company. Let's face it, Wednesday was a hard day for many, but, is it over?
The six month report definitely didn't sugar coat any facts, but, I just can't overlook the first line of the first keypoint - "The trial did not meet its primary endpoint".
The FDA over the last 10 years has approved drugs from different pharmaceuticals after failing to meet their primary endpoints;
- Intercept Pharmaceuticals with their drug Ocaliva (liver disease) in 2016.
- Biogen with their drug Aduhelm (alzheimer's) in June 2021.
- Amgen with their drug Repatha (LDL cholesterol) in 2015.
- AstraZenica with their drug Iressa (lung cancer) in 2015.
- MacroGenetics with their drug Margenza (breast cancer) in 2020.
- Oncopeptides AB with their drug Pepaxto (multiple myeloma) in 2020.
- Neurocrine Biosciences with their drug Crenessity (Congenital Adrenal Hyperplasia) in 2024.
And, even this year, Srepta, with their drug Elevidys for DMD.
The "trial", fair to say has failed. But, has the drug really failed?
Add to My Watchlist
What is My Watchlist?
